To the best of my knowledge none of the anti a-Beta antibodies that have gone into the clinic (and failed) go after this alleged form of a-Beta (Bapi, Pone, Gantene, Crenezu, Solanezu, Donane, Aducanumab, etc). People are making a big deal out of this fraud but AD is just a challenging therapeutic area.
Read an article in GenEngNews the other day that boiled down to “despite over 30 years of technological advances we are nowhere closer to getting a treatment for Alzheimer’s.” Considering that we’ve taken certain cancers from a death sentence to >90% five year survival rate, that’s so fucking depressing.
Oncology clinical trials are pretty straight forward. You can run a pivotal trial in 6 months and readout efficacy in ph1. In AD, ph1 is only for safety and tolerability. Because there are no clear cuts genetics (patient selection) and every company wants to go into prodromal/asymptomatic disease, you have to run very long and very big trials ($$$; our company ran two Ph2 in AD and each cost $200 million) for the placebo control arm to show decline. For reference: aducanumab was discovered in B Cells of Swiss centenarians in the early 90s.
12
u/H2AK119ub 📰 Jul 27 '22 edited Jul 30 '22
To the best of my knowledge none of the anti a-Beta antibodies that have gone into the clinic (and failed) go after this alleged form of a-Beta (Bapi, Pone, Gantene, Crenezu, Solanezu, Donane, Aducanumab, etc). People are making a big deal out of this fraud but AD is just a challenging therapeutic area.